COMPARE · Reviewed July 29, 2026
ADMA vs ALNY
Verdict: Side-by-side breakdown using the Bull Rankings model. ADMA scored 85.0, ALNY scored 74.0 — ADMA leads.
Compare another set
ADMA
ADMA Biologics, Inc.
85
$8.71 · $2.0B
fundamentals as of
Score gap
11.0
ADMA leads
ALNY
Alnylam Pharmaceuticals, Inc.
74
$286.62 · $38.3B
fundamentals as of
The model, pillar by pillar (0–100 each)
ADMA
stronger →← stronger
ALNY
81
Qualityreturns · margins · balance sheet
64
90
Growthrevenue & earnings expansion
100
84
Valuevaluation vs sector peers
63
ADMA is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ADMA
ALNY
$108mC
FCF
$465mC
+11.0%B
Rev
+65.2%A
1.11C
D/E
2.76D
12.8xA-
P/E
72.0xC
0.65A-
PEG
0.49A
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADMA
ALNY
36% below
Price vs fair valuelower is cheaper
250% above
~3%/yr
Growth the price implies10-yr FCF · lower = less priced in
~49%/yr
+20%
1-yr DCF upside
-78%
+56%
5-yr DCF upside
-71%
+132%
10-yr DCF upside
-57%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADMA
Why this score
- Buying back stock
- Durable high returns
- Earnings outpace cash
ALNY
Why this score
- Diluting shareholders
The companies
ADMAADMA Biologics, Inc.
Why now
Biotechnology · market cap $2.0b. Down 57% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. PEG 0.65 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $17.00 (implying +95% upside).
Moat
Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 57% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $38.3b. Down 42% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.49 — paying under fair value for the growth rate. 23 sell-side analysts rate this a Buy with a mean 1-yr target of $432.04 (implying +51% upside).
Moat
ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 167% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.76 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trailing P/E 72.0x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.